1005 related articles for article (PubMed ID: 17159160)
1. Single exposure to a serotonin 1A receptor agonist, (+)8-hydroxy-2-(di-n-propylamino)-tetralin, produces a prolonged heterologous desensitization of serotonin 2A receptors in neuroendocrine neurons in vivo.
Carrasco GA; Van de Kar LD; Jia C; Xu H; Chen Z; Chadda R; Garcia F; Muma NA; Battaglia G
J Pharmacol Exp Ther; 2007 Mar; 320(3):1078-86. PubMed ID: 17159160
[TBL] [Abstract][Full Text] [Related]
2. Prolonged 5-HT1A/5-HT2A receptor cross-talk is absent prior to adulthood in rats.
Petrunich ML; Garcia F; Carrasco GA; Battaglia G
Neuroreport; 2008 Oct; 19(15):1457-61. PubMed ID: 18797297
[TBL] [Abstract][Full Text] [Related]
3. Desensitization of 5-HT1A receptors by 5-HT2A receptors in neuroendocrine neurons in vivo.
Zhang Y; Gray TS; D'Souza DN; Carrasco GA; Damjanoska KJ; Dudas B; Garcia F; Zainelli GM; Sullivan Hanley NR; Battaglia G; Muma NA; Van de Kar LD
J Pharmacol Exp Ther; 2004 Jul; 310(1):59-66. PubMed ID: 15064330
[TBL] [Abstract][Full Text] [Related]
4. Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice.
Li Q; Wichems C; Heils A; Van De Kar LD; Lesch KP; Murphy DL
J Pharmacol Exp Ther; 1999 Dec; 291(3):999-1007. PubMed ID: 10565817
[TBL] [Abstract][Full Text] [Related]
5. Estrogen reduces serotonin-1A receptor-mediated oxytocin release and Galpha(i/o/z) proteins in the hypothalamus of ovariectomized rats.
D'Souza DN; Zhang Y; Damjanoska KJ; Carrasco GA; Sullivan NR; Garcia F; Battaglia G; Doncarlos LL; Muma NA; Van de Kar LD
Neuroendocrinology; 2004; 80(1):31-41. PubMed ID: 15385710
[TBL] [Abstract][Full Text] [Related]
6. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
Gogos A; Kwek P; Chavez C; van den Buuse M
J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
[TBL] [Abstract][Full Text] [Related]
7. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats.
Liu FY; Xing GG; Qu XX; Xu IS; Han JS; Wan Y
J Pharmacol Exp Ther; 2007 Jun; 321(3):1046-53. PubMed ID: 17329553
[TBL] [Abstract][Full Text] [Related]
8. Receptor-genes cross-talk: effect of chronic 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin treatment on the expression of key genes in brain serotonin system and on behavior.
Popova NK; Naumenko VS; Cybko AS; Bazovkina DV
Neuroscience; 2010 Aug; 169(1):229-35. PubMed ID: 20423722
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the functional heterologous desensitization of hypothalamic 5-HT(1A) receptors after 5-HT(2A) receptor activation.
Zhang Y; D'Souza D; Raap DK; Garcia F; Battaglia G; Muma NA; Van de Kar LD
J Neurosci; 2001 Oct; 21(20):7919-27. PubMed ID: 11588165
[TBL] [Abstract][Full Text] [Related]
10. Alterations in 8-hydroxy-2-(dipropylamino)tetralin-induced neuroendocrine responses after 5,7-dihydroxytryptamine-induced denervation of serotonergic neurons.
Van de Kar LD; Li Q; Cabrera TM; Brownfield MS; Battaglia G
J Pharmacol Exp Ther; 1998 Jul; 286(1):256-62. PubMed ID: 9655867
[TBL] [Abstract][Full Text] [Related]
11. Activation of paraventricular nucleus of hypothalamus 5-HT1A receptor on sodium intake.
Villa Pde S; Camargo GM; Camargo LA; Saad WA
Regul Pept; 2007 May; 140(3):142-7. PubMed ID: 17218026
[TBL] [Abstract][Full Text] [Related]
12. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats.
Fornal CA; Martin FJ; Metzler CW; Jacobs BL
J Pharmacol Exp Ther; 1999 Oct; 291(1):229-38. PubMed ID: 10490909
[TBL] [Abstract][Full Text] [Related]
13. 5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome.
Osei-Owusu P; James A; Crane J; Scrogin KE
J Pharmacol Exp Ther; 2005 Jun; 313(3):1324-30. PubMed ID: 15743927
[TBL] [Abstract][Full Text] [Related]
14. Thermogenesis in brown adipose tissue: increase by 5-HT2A receptor activation and decrease by 5-HT1A receptor activation in conscious rats.
Ootsuka Y; Blessing WW
Neurosci Lett; 2006 Mar; 395(2):170-4. PubMed ID: 16293365
[TBL] [Abstract][Full Text] [Related]
15. Phrenic nerve activity is enhanced by 5-HT1A receptor agonist 8-OH-DPAT in spontaneously breathing anesthetized rats.
Valic M; Pecotic R; Dogas Z
J Physiol Pharmacol; 2008 Mar; 59(1):17-25. PubMed ID: 18441384
[TBL] [Abstract][Full Text] [Related]
16. Hypothalamic-pituitary-adrenal responses to 5-HT1A and 5-HT2A/C agonists are differentially altered in female and male rats prenatally exposed to ethanol.
Hofmann CE; Ellis L; Yu WK; Weinberg J
Alcohol Clin Exp Res; 2007 Feb; 31(2):345-55. PubMed ID: 17250628
[TBL] [Abstract][Full Text] [Related]
17. Studies on the neuroendocrine role of serotonin.
Jørgensen HS
Dan Med Bull; 2007 Nov; 54(4):266-88. PubMed ID: 18208678
[TBL] [Abstract][Full Text] [Related]
18. The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinociception in rats in situ and in vivo.
Guenther U; Manzke T; Wrigge H; Dutschmann M; Zinserling J; Putensen C; Hoeft A
Anesth Analg; 2009 Apr; 108(4):1169-76. PubMed ID: 19299781
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine(1A) receptors in hypothalamus.
Serres F; Muma NA; Raap DK; Garcia F; Battaglia G; Van de Kar LD
J Pharmacol Exp Ther; 2000 Jul; 294(1):296-301. PubMed ID: 10871325
[TBL] [Abstract][Full Text] [Related]
20. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist.
Piper BJ; Vu HL; Safain MG; Oliver AJ; Meyer JS
J Pharmacol Exp Ther; 2006 May; 317(2):838-49. PubMed ID: 16434566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
